Most clinicians treat resistant infections as a clinical puzzle: culture the organism, narrow the regimen, move on. But an opinion piece in MedPage Today argues that this approach ignores the source of the problem. The author notes that about 70% of antibiotics important to human medicine in the U.S. are sold for use in food animals, largely to keep crowded, stressed livestock alive rather than to treat sick animals. That use pattern, she says, is a structural input to industrial meat production, and clinicians inherit its consequences without any visibility or control.
The farm-to-clinic link is not theoretical. The piece cites the emergence of the transferable resistance gene mcr-1, which spread globally after colistin was used as a growth promoter on Chinese pig farms. When China banned colistin as a feed additive in 2017, resistance measurably fell in both animals and people. That natural experiment, the author argues, shows that a drug can become more usable again because of a change in food-animal policy, not clinical practice.
The author does not call for eliminating veterinary antibiotics entirely—sick animals still need treatment. But she argues that stewardship efforts focused only on hospitals and clinics are managing a downstream symptom. She suggests two underused levers for clinicians: counseling patients toward more plant-forward diets to reduce demand for confinement-raised animal protein, and pushing hospital food-service contracts toward more sustainable purchasing. She also urges clinicians to advocate for farm-level regulation through professional societies, as many already do for vaccine or opioid policy. Regulation, she writes, is fighting a demand curve it did not create, but diet is a piece of that curve clinicians can influence from the exam room.